Announcements Trials
Browse Landscape

Phase

Phase 3 1

Status

Withdrawn 1Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other 1Endocrine 1CNS 1

Conditions

Pituitary Diseases 1Obesity 1Neoplasms 1Hyperinsulinism 1Craniopharyngioma 1

Interventions

Cyclophosphamide 1492Cisplatin 1414Paclitaxel 1317Radiotherapy 1261Carboplatin 1250Gemcitabine 1215Docetaxel 1109Bevacizumab 1030Fluorouracil 894Doxorubicin 792Dexamethasone 748Rituximab 719Capecitabine 716Oxaliplatin 700pembrolizumab 680Etoposide 678Irinotecan 634Filgrastim 621Cytarabine 586Leucovorin 579Nivolumab 558Vincristine 515Prednisone 475Cetuximab 465Bortezomib 459Erlotinib Hydrochloride 456Trastuzumab 447Methotrexate 438Lenalidomide 427Pemetrexed 420

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Completed × Interventional × Diazoxide × Clear all
NCT00306683 2011-02-18

Effect of Diazoxide on the Obesity Secondary to Hypothalamic-pituitary Lesions

Assistance Publique - Hôpitaux de Paris

Phase 3 Completed
40 enrolled
CNSEndocrineOther

Craniopharyngioma, Hyperinsulinism, Neoplasms, Obesity, Pituitary Diseases

Data powered by HemOnc (CC BY 4.0) Colophon âš¡